메뉴 건너뛰기




Volumn 33, Issue 1, 2008, Pages 129-136

Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation

Author keywords

Bortezomib; Osteoclast differentiation; Thalidomide

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; BORTEZOMIB; CC 6032; IMMUNOMODULATING AGENT; LENALIDOMIDE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG; BONE MORPHOGENETIC PROTEIN; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; IMMUNOLOGIC FACTOR; POMALIDOMIDE; PYRAZINE DERIVATIVE; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA;

EID: 51049087523     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.33.1.129     Document Type: Article
Times cited : (39)

References (35)
  • 1
    • 0016804136 scopus 로고
    • A clinical staging system for multiple myeloma
    • Durie BGM and Salmon SE: A clinical staging system for multiple myeloma. Cancer 36: 842-854, 1975.
    • (1975) Cancer , vol.36 , pp. 842-854
    • Durie, B.G.M.1    Salmon, S.E.2
  • 2
    • 0025098172 scopus 로고
    • Effect of glucocorticoids on the biologic activity of myeloma cells: Inhibition of interleukin-1β ostoclasts activating factor-induced bone resorption
    • Ishikawa H, Tanaka H, Iwato K, Tanabe O, Asaoku H, Nobuyoshi M, Yamamoto I, Kawano M and Kuramoto A: Effect of glucocorticoids on the biologic activity of myeloma cells: Inhibition of interleukin-1β ostoclasts activating factor-induced bone resorption. Blood 75: 715-720, 1990.
    • (1990) Blood , vol.75 , pp. 715-720
    • Ishikawa, H.1    Tanaka, H.2    Iwato, K.3    Tanabe, O.4    Asaoku, H.5    Nobuyoshi, M.6    Yamamoto, I.7    Kawano, M.8    Kuramoto, A.9
  • 3
    • 0037105599 scopus 로고    scopus 로고
    • Abe M, Hiura K, Wilde J, Moriyama k, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D and Matsumoto T: Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100: 2195-2202, 2002.
    • Abe M, Hiura K, Wilde J, Moriyama k, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D and Matsumoto T: Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100: 2195-2202, 2002.
  • 5
    • 0037443533 scopus 로고    scopus 로고
    • RANK ligand and osteoprotegerin in myeloma bone disease
    • Sezer O, Heider U, Zavrski I, Kuhne CA and Hofbauer LC: RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101: 2094-2098, 2003.
    • (2003) Blood , vol.101 , pp. 2094-2098
    • Sezer, O.1    Heider, U.2    Zavrski, I.3    Kuhne, C.A.4    Hofbauer, L.C.5
  • 6
    • 0346363760 scopus 로고    scopus 로고
    • The role of Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
    • Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B and Shaughnessy JD: The role of Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494, 2003.
    • (2003) N Engl J Med , vol.349 , pp. 2483-2494
    • Tian, E.1    Zhan, F.2    Walker, R.3    Rasmussen, E.4    Ma, Y.5    Barlogie, B.6    Shaughnessy, J.D.7
  • 8
    • 20844451019 scopus 로고    scopus 로고
    • High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: Possible role of bortezomib on osteoblast differentiation
    • Shimazaki C, Uchida R, Nakano S, Namura K, Fuchida SI, Okano A, Okamoto M and Inaba T: High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia 19: 1102-1103, 2005.
    • (2005) Leukemia , vol.19 , pp. 1102-1103
    • Shimazaki, C.1    Uchida, R.2    Nakano, S.3    Namura, K.4    Fuchida, S.I.5    Okano, A.6    Okamoto, M.7    Inaba, T.8
  • 12
    • 0029803056 scopus 로고    scopus 로고
    • A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet
    • Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y and Ueno K: A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 19: 1518-1520, 1996.
    • (1996) Biol Pharm Bull , vol.19 , pp. 1518-1520
    • Ishiyama, M.1    Tominaga, H.2    Shiga, M.3    Sasamoto, K.4    Ohkura, Y.5    Ueno, K.6
  • 14
    • 0035300479 scopus 로고    scopus 로고
    • The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
    • Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001.
    • (2001) Cancer Res , vol.61 , pp. 3071-3076
    • Hideshima, T.1    Richardson, P.2    Chauhan, D.3    Palombella, V.J.4    Elliott, P.J.5    Adams, J.6    Anderson, K.C.7
  • 16
    • 19944427451 scopus 로고    scopus 로고
    • Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells
    • Luo Q, Kang Q, Si W, Jiang W, Park JK, Peng Y, Li X, Luu HH, Luo J, Montag AG, Haydon RC and He TC: Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem 279: 55958-55968, 2004.
    • (2004) J Biol Chem , vol.279 , pp. 55958-55968
    • Luo, Q.1    Kang, Q.2    Si, W.3    Jiang, W.4    Park, J.K.5    Peng, Y.6    Li, X.7    Luu, H.H.8    Luo, J.9    Montag, A.G.10    Haydon, R.C.11    He, T.C.12
  • 18
    • 33748287079 scopus 로고    scopus 로고
    • Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, De la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, De Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper, F, Mateo G, Esseltine DL, van de Velde H and San Miguel JF: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108: 2165-2172, 2006.
    • Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, De la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, De Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper, F, Mateo G, Esseltine DL, van de Velde H and San Miguel JF: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108: 2165-2172, 2006.
  • 20
    • 33746160660 scopus 로고    scopus 로고
    • Proteasome inhibitor bortezomib for the treatment of multiple myeloma
    • Cavo M: Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 20: 1341-1352, 2006.
    • (2006) Leukemia , vol.20 , pp. 1341-1352
    • Cavo, M.1
  • 21
    • 33644843725 scopus 로고    scopus 로고
    • Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P and Boccadoro M: Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367: 825-831, 2006.
    • Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P and Boccadoro M: Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367: 825-831, 2006.
  • 27
    • 27644591608 scopus 로고    scopus 로고
    • Properties of thalidomide and its analogues: Implications for anticancer therapy. The AAPS J
    • Teo SK: Properties of thalidomide and its analogues: implications for anticancer therapy. The AAPS J 7: E14-E19, 2005.
    • (2005) , vol.7
    • Teo, S.K.1
  • 31
    • 0036884062 scopus 로고    scopus 로고
    • Molecular mechanisms of novel therapeutic approaches for multiple myeloma
    • Hideshima T and Anderson KC: Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev 2: 927-937, 2002.
    • (2002) Nat Rev , vol.2 , pp. 927-937
    • Hideshima, T.1    Anderson, K.C.2
  • 35
    • 4944230728 scopus 로고    scopus 로고
    • Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion
    • Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D and Matsumoto T: Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104: 2484-2491, 2004.
    • (2004) Blood , vol.104 , pp. 2484-2491
    • Abe, M.1    Hiura, K.2    Wilde, J.3    Moriyama, K.4    Hashimoto, T.5    Ozaki, S.6    Wakatsuki, S.7    Kosaka, M.8    Kido, S.9    Inoue, D.10    Matsumoto, T.11


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.